Heart failure & cardiomyopathiesMeta-analysis
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
- Pooled analysis of the I-PRESERVE, TOPCAT, PARAGON and DELIVER randomised trials
- TOPCAT Americas region only
Authors' conclusion
The same NT-proBNP concentration predicts a substantially higher absolute risk of adverse outcomes for people with heart failure and reduced kidney function, compared with those with preserved kidney function.
Study context
- Population
- Patients with HF and mildly reduced or preserved EF with baseline NT-proBNP and estimated glomerular filtration rate (eGFR)3,092 primary outcomes
- Participants
- 14,831 patients
- Comparison
- NT-proBNP and outcomes across eGFR categories
- Outcome
- HF hospitalization or CV death
- Follow-up
- Median 33.5 months
Pooled result
Primary outcome per doubling of NT-proBNP
Hazard ratio
1.37
95% CI 1.34–1.41
Each doubling in NT-proBNP
HR 1.37 (95% CI 1.34–1.41)
Each doubling in NT-proBNP, as printed
As reported in the abstract
Further pooled results
NT-proBNP increase per 10 mL/min/1.73 m² lower eGFR
- NT-proBNP increase per 10 mL/min/1.73 m² lower eGFR: P for nonlinearity < 0.001
All outcomes studied, incl. CV and non-CV death
- Similar patterns observed
Original publication
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. Published 31 August 2024. doi:10.1016/j.jchf.2024.08.009
Summarised from the published abstract; every number is checked against it